CanSino Biologics, Inc. Class H (6185) AI Stock Analysis

• Market Cap: HK$14.87B
• Dividend Yield: N/A
• Average Volume (3M): 3.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: 45.73%
• EPS Growth: 80.77%
• Country: HK
• Employees: 1,105
• Sector: Healthcare
• Sector Strength: 51
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 132,670,900
• 10 Day Avg. Volume: 2,560,472
• 30 Day Avg. Volume: 3,267,077
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$59.30
• Price Target Upside: 21.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 49 Neutral
• Price Target: HK$52.00 ▲(6.43% Upside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and profitability, and negative cash flows. While technical indicators show bullish momentum, the overbought condition suggests caution. The valuation is weak due to ongoing losses and lack of dividend yield.

CanSino Biologics, Inc. Class H Business Overview & Revenue Model

Company Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

How the Company Makes Money

CanSino Biologics, Inc. generates revenue primarily through the sale and licensing of its vaccine products. The company's key revenue streams include direct sales of vaccines to government health departments, international organizations, and healthcare providers. Additionally, CanSino engages in partnerships and collaborations with other pharmaceutical companies and research institutions to co-develop and commercialize new vaccine products, which can result in milestone payments, royalties, or joint venture earnings. The company's financial performance is significantly influenced by its ability to successfully bring new vaccines to market, secure regulatory approvals, and expand its distribution network both domestically and internationally.

CanSino Biologics, Inc. Class H Financial Statement Overview

Summary

CanSino Biologics is facing significant financial challenges with declining revenues and profitability, ongoing operational and net losses, and negative cash flows. The balance sheet shows a strong equity position, but the increasing debt-to-equity ratio raises concerns about financial sustainability.

Income Statement

CanSino Biologics showed a significant decline in revenue and profitability over the past few years. The company had a positive revenue growth in 2024, but it still incurred a net loss. Gross profit margins are positive in 2024, but the net profit margin remains deeply negative due to high operating losses. The company's EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a relatively high level of equity compared to total assets, indicating financial stability. However, the debt-to-equity ratio has increased, which could pose a risk if revenue and profitability do not improve. The company's return on equity is negative due to ongoing losses, but it still maintains a solid equity base.

Cash Flow

The cash flow statement reflects challenges in generating cash from operations, with negative operating and free cash flow. The free cash flow growth rate is negative, which is concerning for long-term sustainability. The company is investing heavily, which may benefit future growth if managed efficiently.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	846.34M	345.18M	1.03B	4.30B	18.54M
Gross Profit	601.91M	-876.02M	-186.61M	3.00B	4.74M
EBITDA	-134.84M	-1.65B	-1.03B	1.98B	-402.97M
Net Income	-378.88M	-1.48B	-964.76M	1.91B	-358.49M
Balance Sheet
Total Assets	7.96B	9.32B	11.47B	11.87B	6.75B
Cash, Cash Equivalents and Short-Term Investments	3.20B	4.12B	5.95B	7.78B	5.11B
Total Debt	2.01B	2.70B	2.70B	1.37B	142.54M
Total Liabilities	3.05B	4.03B	4.22B	3.33B	677.22M
Stockholders Equity	4.91B	5.27B	6.75B	8.00B	6.07B
Cash Flow
Free Cash Flow	-626.42M	-1.53B	-2.96B	811.42M	-740.16M
Operating Cash Flow	-168.79M	-916.25M	-1.89B	2.01B	-469.39M
Investing Cash Flow	3.96M	-449.65M	-1.19B	-2.53B	-182.71M
Financing Cash Flow	-334.18M	-7.58M	854.60M	1.56B	4.94B

CanSino Biologics, Inc. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Positive. The current price of 48.86 is below the 20-day moving average (MA) of 49.07, above the 50-day MA of 42.64, and above the 200-day MA of 34.69, indicating a neutral trend. The MACD of 1.64 indicates Positive momentum. The RSI at 54.76 is Neutral, neither overbought nor oversold. The STOCH value of 25.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6185.

CanSino Biologics, Inc. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.26	-41.41%	2.22%	22.87%	-2.01%
6185	49 Neutral	HK$14.87B	―	-3.34%	―	45.73%	80.77%
GZPHF	―	$5.74B	9.93	7.53%	7.16%	―	―
LVZPF	―	$4.79B	13.62	15.72%	3.94%	―	―
SFOSF	―	$10.10B	13.56	6.88%	2.02%	―	―
640	―	€3.36B	9.23	5.89%	―	―	―
3692	73 Outperform	HK$218.11B	41.49	16.09%	0.93%	8.68%	0.82%

CanSino Biologics, Inc. Class H Corporate Events

CanSino Biologics Gains Approval for Polio Vaccine Clinical Trials in China

CanSino Biologics Inc. has received approval from the National Medical Products Administration of China to conduct clinical trials for its Recombinant Trivalent Poliomyelitis Vaccine. This vaccine, which does not contain viral genetic material and is produced without using live viruses, is expected to have strong safety and immunogenicity profiles. The World Health Organization recommends non-infectious polio VLP-based vaccines, like CanSino’s, as a preferred option for future polio prevention, potentially positioning the company as a key player in the post-eradication polio vaccine market.

CanSino Biologics Gains Approval for New Pneumococcal Vaccine

CanSino Biologics Inc. has received approval from China’s National Medical Products Administration for its 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13i). This vaccine, which uses advanced technology to enhance immunogenicity and safety, is the first in the company’s pneumococcal vaccine portfolio to gain such approval. The launch of PCV13i is expected to strengthen CanSino’s product portfolio and improve marketing efficiency, aligning with its existing high-end vaccine offerings.

CanSino Biologics Gains Approval for Inhaled TB Vaccine Trial in Indonesia

CanSino Biologics Inc. announced the approval of its Phase I clinical trial for an inhaled tuberculosis booster vaccine in Indonesia. This development is significant as it addresses the limitations of the existing Bacillus Calmette-Guerin vaccine by offering a booster that enhances mucosal immunity, potentially improving tuberculosis prevention efforts in high-burden regions.

CanSino Biologics Sets Agenda for 2024 AGM with Key Resolutions

CanSino Biologics Inc. has announced the agenda for its 2024 Annual General Meeting, scheduled for June 4, 2025, in Tianjin, China. The meeting will cover several key resolutions, including the approval of the 2024 financial reports, profit distribution plans, and reappointment of auditors. Additionally, shareholders will consider granting mandates for share issuance and repurchase, which could impact the company’s capital structure and market operations.